Biorestorative Therapies vs Cardiff Oncology
Cardiff Oncology is the larger business, with $593,000 of revenue in fiscal 2025 against $359,700 for Biorestorative Therapies (1.6 times as much). Biorestorative Therapies grew faster (-10.3% against -13.2%). Biorestorative Therapies kept more of each dollar of sales as profit: a net margin of -3959.4% against -7732.0%.
| Latest fiscal year | Biorestorative TherapiesBRTX, 2025 | Cardiff OncologyCRDF, 2025 |
|---|---|---|
| Revenue | $359,700 | $593,000 |
| Revenue growth | -10.3% | -13.2% |
| Net income | −$14.2m | −$45.9m |
| Operating margin | — | — |
| Net margin | -3959.4% | -7732.0% |
| Return on equity | — | -71.5% |
| Free cash flow | −$10.9m | −$38.0m |
| Cash | $1.5m | $17.5m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 14 | 31 |
| Market value | $36.4m | $58.6m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 5 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 4 buys, 0 sales |